1. Home
  2. ZNTL vs FHTX Comparison

ZNTL vs FHTX Comparison

Compare ZNTL & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZNTL
  • FHTX
  • Stock Information
  • Founded
  • ZNTL 2014
  • FHTX 2015
  • Country
  • ZNTL United States
  • FHTX United States
  • Employees
  • ZNTL N/A
  • FHTX N/A
  • Industry
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • FHTX Medicinal Chemicals and Botanical Products
  • Sector
  • ZNTL Health Care
  • FHTX Health Care
  • Exchange
  • ZNTL Nasdaq
  • FHTX Nasdaq
  • Market Cap
  • ZNTL 300.4M
  • FHTX 310.9M
  • IPO Year
  • ZNTL 2020
  • FHTX 2020
  • Fundamental
  • Price
  • ZNTL $3.70
  • FHTX $5.90
  • Analyst Decision
  • ZNTL Buy
  • FHTX Buy
  • Analyst Count
  • ZNTL 7
  • FHTX 3
  • Target Price
  • ZNTL $13.14
  • FHTX $13.00
  • AVG Volume (30 Days)
  • ZNTL 1.6M
  • FHTX 143.7K
  • Earning Date
  • ZNTL 08-07-2024
  • FHTX 08-02-2024
  • Dividend Yield
  • ZNTL N/A
  • FHTX N/A
  • EPS Growth
  • ZNTL N/A
  • FHTX N/A
  • EPS
  • ZNTL N/A
  • FHTX N/A
  • Revenue
  • ZNTL $40,560,000.00
  • FHTX $33,896,000.00
  • Revenue This Year
  • ZNTL N/A
  • FHTX N/A
  • Revenue Next Year
  • ZNTL N/A
  • FHTX $8.63
  • P/E Ratio
  • ZNTL N/A
  • FHTX N/A
  • Revenue Growth
  • ZNTL N/A
  • FHTX 64.41
  • 52 Week Low
  • ZNTL $3.27
  • FHTX $2.70
  • 52 Week High
  • ZNTL $29.03
  • FHTX $9.97
  • Technical
  • Relative Strength Index (RSI)
  • ZNTL 30.12
  • FHTX 51.91
  • Support Level
  • ZNTL $3.83
  • FHTX $5.62
  • Resistance Level
  • ZNTL $4.79
  • FHTX $6.98
  • Average True Range (ATR)
  • ZNTL 0.44
  • FHTX 0.58
  • MACD
  • ZNTL 0.26
  • FHTX 0.09
  • Stochastic Oscillator
  • ZNTL 28.29
  • FHTX 51.13

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: